Nanotechnology Drug Delivery System In Diabetes

Authors

  • Shivam Kumar Yadav , Venu Anand Das Vaishnav, Rajni Yadav

DOI:

https://doi.org/10.47750/pnr.2022.13.S10.647

Abstract

Diabetes mellitus (DM) has been recognised by mankind for over 2000 years. A complete lack of insulin, a relative lack of insulin, or insulin resistance is all symptoms of diabetes mellitus (DM), a set of metabolic illnesses. Age, ethnicity, and manner of life are three causes of the rise in diabetes prevalence. The best use of currently available medications is one of the current issues in the management of diabetes, as it's important to maintain optimal glucose, blood pressure, and cholesterol control while minimising complications. The use of nanotechnology is emerging as the most alluring and promising of these approaches. Nanoparticles have the potential to be employed as efficient drug delivery systems in situations where there are barriers or unfavourable environments for macromolecules because of their shape-dependent properties, especially when at least one of their dimensions is smaller than 100 nm. Diabetic patients can get insulin orally, with advantages that reflect both the physiological fate of the hormone as well as the discomfort and suffering brought on by injections. This article provides a brief overview of the subject, with appropriate references to original research articles and review articles on previous and current research findings about nanotechnology drug delivery system.

Downloads

Published

2022-12-31 — Updated on 2022-12-31

Issue

Section

Articles

How to Cite

Nanotechnology Drug Delivery System In Diabetes. (2022). Journal of Pharmaceutical Negative Results, 5328-5333. https://doi.org/10.47750/pnr.2022.13.S10.647